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Take-home message: This prospective
cohort study indicates that in-hospital
mortality substantially underestimates
mortality at 1 year following ARDS. The
independent risk factors for death in
hospital survivors of ARDS were age and
comorbidities rather than ARDS-related
severity of illness measures. These findings
highlight the prevalence of serious
comorbidities among ARDS patients in the
modern era and suggest that underlying
comorbidities are most predictive of the
long-term trajectory of ARDS patients.
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Abstract Purpose: Advances in
supportive care and ventilator man-
agement for acute respiratory distress
syndrome (ARDS) have resulted in
declines in short-term mortality, but
risks of death after survival to hospi-
tal discharge have not been well
described. Our objective was to
quantify the difference between short-
term and long-term mortality in
ARDS and to identify risk factors for
death and causes of death at 1 year
among hospital survivors. Meth-
ods: This multi-intensive care unit,
prospective cohort included patients
with ARDS enrolled between January
2006 and February 2010. We deter-
mined the clinical characteristics
associated with in-hospital and 1-year
mortality among hospital survivors
and utilized death certificate data to
identify causes of death. Results: Of
646 patients hospitalized with ARDS,
mortality at 1 year was substantially
higher (41 %, 95 % CI 37–45 %)
than in-hospital mortality (24 %,
95 % CI 21–27 %), P \ 0.0001.
Among 493 patients who survived to
hospital discharge, the 110 (22 %)
who died in the subsequent year were
older (P \ 0.001) and more likely to
have been discharged to a nursing
home, other hospital, or hospice
compared to patients alive at 1 year
(P \ 0.001). Important predictors of
death among hospital survivors were
comorbidities present at the time of
ARDS, and not living at home prior
to admission. ARDS-related measures
of severity of illness did not emerge
as independent predictors of mortality
in hospital survivors. Conclu-
sions: Despite improvements in
short-term ARDS outcomes, 1-year
mortality is high, mostly because of the
large burden of comorbidities, which
are prevalent in patients with ARDS.
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Introduction
The last decade has seen many advancements in care for
patients with acute respiratory distress syndrome (ARDS)
including improvements in ventilator management [1, 2],
noninvasive mechanical ventilation strategies [3–5], sepsis
management [6], and intensive care unit system changes
[7, 8]. More patients with ARDS are now surviving to
hospital discharge, a phenomenon that has been reported
in both observational studies and randomized trials [9–11].
For example, 60-day mortality decreased from 40 % in the
traditional tidal volume arm of the ARDS network ARMA
study published in 2000 to 21 % in the most recent ARDS
network trial published in 2011, in spite of increased
severity of illness and more comorbidities in the more
recent trial [1, 12]. However, less is known about the
epidemiology of long-term survival in ARDS, particularly
in the context of increasing severity of illness and
comorbidities among ICU patients today [13].
Initial studies of long-term outcomes in ARDS found
that in-hospital survival from ARDS provided a good
estimate of long-term survival [14–17]; however, these
populations are not reflective of ARDS patients in modern
practice. In-hospital mortality in these studies was higher
at 37–40 %, as these cohorts predated widespread
implementation of low tidal volume ventilation. Further-
more, patients who survived to hospital discharge and
were selected for these studies were young (mean age
mid-40 s), had few coexisting conditions, and lower
severity of illness on presentation. More recent data
demonstrate a widening difference between ARDS sur-
vival at discharge and long-term follow-up [11, 18, 19].
This ‘‘survival gap’’ suggests that while modern ICU
interventions have resulted in short-term improvements in
ARDS survival, the overall survival after ARDS may not
have improved. Temporal changes in ICU patient char-
acteristics including increased severity of illness and more
comorbid illnesses may explain some of the changes in
trajectory of illness following discharge [13].
Although factors that predict short-term mortality
have been well described [20–29], a better understanding
of predictors of long-term mortality in ARDS is required
for improved prognostication and a better understanding
of the effects of ICU interventions on long-term outcomes
[19]. A small study predating low tidal volume ventilation
found that comorbidities, ARDS risk factor, and age were
most highly associated with mortality 6 months following
ARDS diagnosis [30], but the influence of increased
severity of illness over time has not been assessed. A
more recent study found that the survival benefits of
adherence to low tidal volume ventilation persisted at
2 years follow-up, suggesting that modern changes in
clinical practice may provide long-standing improve-
ments in survival [19]. However, this study excluded
sicker patients with cancer or life-limiting disease—
diagnoses that are frequent in patients presenting with
ARDS. The predictors and causes of death in a broad
sample of patients surviving to hospital discharge with
ARDS are not known.
The purpose of the current study was to (1) quantify
the gap between in-hospital and 1-year ARDS mortality in
modern practice, (2) identify the most influential risk
factors for death at 1 year among hospital survivors in a
large, multi-ICU prospective cohort study of patients with
ARDS, and (3) examine causes of death among patients
dying in the year after diagnosis of ARDS. Some of these
data have previously been presented in the form of an
abstract [31].
Materials and methods
Subjects
The study subjects were drawn from the validation of
biomarkers in acute lung injury diagnosis (VALID)
study, an ongoing prospective, multi-ICU cohort study
of critically ill patients at Vanderbilt University Medical
Center, a tertiary medical center in Nashville, TN. The
inclusion criteria and exclusion criteria of VALID have
been reported previously and are described in the sup-
plemental appendix [32]. Specifically, patients with
severe chronic lung disease were excluded, but patients
with other underlying comorbidities including advanced
cancer and HIV were not excluded. The study was
approved by the Vanderbilt University Institutional
Review Board.
For this analysis, we included patients enrolled
between January 2006 and February 2010 who had or
developed acute lung injury (ALI)/ARDS during the first
4 days after admission to the ICU. During the study
period, there were a total of 2,181 total patients enrolled
in VALID of whom, 1,894 had at least one risk factor for
ARDS. Of these, the current study focused on the 646
who met the American European consensus conference
(AECC) criteria for ALI/ARDS [33].
Data collection
Data collection and definitions have been described pre-
viously [32]. Diagnosis of ALI/ARDS was defined by the
AECC definition (PaO2/FiO2 B300 mmHg for ALI and
PaO2/FiO2 B200 mmHg for ARDS) [33], and could be
established at any time during the first 4 days in the ICU.
Both mechanically ventilated (defined as invasive
mechanical ventilation within 4 days of AECC ALI/
ARDS diagnosis) and not mechanically ventilated
patients meeting AECC criteria were included in our
primary analysis. In a sensitivity analysis, we also con-
sidered the Berlin definition for ARDS [34, 35]. Berlin
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severity levels were defined as mild (200 mmHg \PaO2/
FiO2 B300 mmHg with PEEP or CPAP C5 cmH2O),
moderate (100 mmHg \PaO2/FiO2 B200 mmHg with
PEEP C5 cmH2O), and severe (PaO2/FiO2 B100 mmHg
with PEEP C5 cmH2O). For both AECC and Berlin
definitions, the ratio of pulse oximetric saturation to
fraction of inspired oxygen (SpO2/FiO2) was used as a
validated surrogate for PaO2/FiO2 among patients without
an arterial blood gas measurement at the time of ALI/
ARDS diagnosis: SpO2/FiO2 = 64 ? 0.84 9 (PaO2/
FiO2) [36]. The discharge location for patients who sur-
vived hospitalization was categorized as home,
rehabilitation hospital, nursing home, hospice, or other
acute care hospital. The lung injury score [37], Brussels
organ failure [38], and definitions for sepsis, pneumonia,
aspiration, and trauma are included in the supplemental
appendix.
Outcome measures
All patients were followed until death or for at least 1 year
after study enrollment. Short-term mortality was defined as
all-cause mortality during hospitalization. Long-term
mortality was defined as all-cause mortality 1 year fol-
lowing enrollment in VALID in patients who survived to
hospital discharge. Patient deaths were identified by med-
ical record review and query of the social security death
index (SSDI) [39]. Causes of death were determined by
review of death certificate data obtained from the Ten-
nessee Vital Records Office of the Tennessee Department
of Health. Underlying causes of death were categorized as
infection, malignancy (primary, metastatic, or hemato-
logic), cardiovascular, respiratory, gastrointestinal/hepatic,
trauma, or other causes (listed in supplemental appendix)
based on ICD-9 coding of the primary cause of death on
the death certificate.
Statistical analysis
We used t tests, chi-squared tests, and Fisher’s exact tests
as appropriate to compare baseline demographics and
clinical risk factors across groups. Descriptive statistics
and McNemar’s were used to compare in-hospital and
1-year mortality. Since all events were accounted for over
the year of follow-up, logistic regression was used to
analyze associations between candidate risk factors and
mortality. Kaplan–Meier survival plots demonstrate the
time from discharge to death in hospital survivors and the
log-rank test was used to estimate differences according
to discharge location. Clinical characteristics associated
with 1-year mortality with P \ 0.10 on bivariable ana-
lysis were entered into a stepwise elimination model to
retain potential risk factors if they remained associated at
a P value of less than 0.05. Because of the modest number
of outcomes, the forward stepwise elimination was used
to maintain model parsimony. In a sensitivity analysis, we
analyzed only patients meeting the Berlin definition of
ARDS [34]. Analyses were performed using STATA
version 10 (STATA Corp, College Station, TX). Statis-
tical significance was defined as a two-tailed P \ 0.05 for
all analyses.
Results
Clinical characteristics and outcomes
Among 646 patients with ALI/ARDS, the proportion of
patients who died increased from 24 % (n = 153, 95 %
CI 21–27 %) during hospitalization to 41 % (n = 263,
95 % CI 37–45 %) during the year after discharge
(P \ 0.0001). One-year mortality was higher than in-
hospital mortality regardless of ALI/ARDS etiology
(Supplemental Fig. 1). In the subset of patients with
2-year outcomes available (n = 527, 82 %), the 2-year
cumulative incidence of death was 54 % (n = 282, 95 %
CI 49–59 %, P = 0.0004).
In a sensitivity analysis of 551 patients meeting the
Berlin definition of ARDS [34] (excluded 95 patients: 87
non-mechanically ventilated in first 4 days of enrollment;
two patients with missing PEEP; two patients with
PEEP \5 cmH2O; and four patients not meeting hypox-
emia criteria on day otherwise meeting all Berlin criteria)
we found similar rates of hospital and 1-year mortality
(Supplemental Table 1). Severity of ARDS defined by
Berlin levels (mild, moderate, severe) was associated with
in-hospital mortality but not with mortality at 1-year
among hospital survivors.
Comparison of baseline characteristics by hospital
and 1-year outcomes
Demographics, comorbidities, and initial clinical charac-
teristics did not differ substantially between those who
died early (in hospital) and those who died over the
subsequent year (Table 1). Patients who died in the hos-
pital (n = 153) were more likely to have a hematologic
malignancy and less likely to have COPD or metastatic
cancer than patients who died after surviving hospital-
ization but were otherwise demographically similar. In
addition, there was no difference in underlying cause of
ALI/ARDS although patients who died during hospital-
ization had a lower P/F ratio and a higher incidence
of hepatic failure compared to those dying after
hospitalization.
By contrast, compared to patients who died in the year
following hospital discharge (n = 110), survivors at
1 year (n = 383) were younger, were more likely to have
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been admitted through the emergency department and had
substantially fewer comorbidities such as COPD, HIV,
diabetes, chronic heart failure, chronic kidney disease, or
malignancy (Table 1). In addition, patients who were
alive at 1 year were more likely to have trauma and less
likely to have sepsis as the cause of ALI/ARDS. Increased
severity of illness on presentation was associated with
higher 1-year mortality among patients who survived
hospitalization: respiratory rate, APACHE II score, pre-
sence of coagulation failure, renal failure, and circulatory
failure were all significantly associated with death after
discharge (Table 1).
Comparison of hospital course between hospital
survivors who were dead or alive at 1 year
Among patients with ALI/ARDS who survived hospital-
ization, those who survived to 1 year had significantly
shorter time from hospital admission to ICU admission,
lower creatinine at discharge, and were more likely to be
discharged home or to a rehabilitation facility and less
likely to be discharged to a nursing home or hospice
facility (Table 2). Specifically, discharge destination
among hospital survivors was strongly associated with
long-term mortality (Fig. 1) (P \ 0.001). There were no
differences in ICU length of stay (P = 0.76) or duration
of mechanical ventilation (P = 0.62) between hospital
survivors that died and survived at 1-year follow-up.
Independent predictors of 1-year mortality
after discharge
Stepwise elimination identified several baseline charac-
teristics as independent predictors of mortality among
hospital survivors. These included age and severe comor-
bidities: HIV, metastatic cancer, hematologic malignancy,
non-metastatic cancer, and chronic renal disease (Table 3).
Trauma as a cause of ARDS and living at home prior to
hospitalization were strong independent predictors of
decreased odds of mortality at 1 year. Increased length of
hospital stay was the only characteristic of hospitalization
that was independently associated with increased odds of
death at 1 year among hospital survivors. Severity of illness
measures including LIS, APACHE II, organ failure, and
PaO2/FiO2 did not emerge as independent predictors of
mortality in survivors. The C-statistic for the final adjusted
model was 0.81. Predictors of 1-year mortality among
survivors were similar after excluding 23 patients dis-
charged to hospice, and characteristics associated with
1-year mortality among those surviving the hospitalization
were similar to those associated with overall 1-year mor-
tality (data not shown).
Causes of death
Death certificate data was available for 244 (93 %) of the
263 patients who died within 1 year of enrollment.
Overall, the most common underlying cause of death both
in the hospital and among hospital survivors was malig-
nancy (Fig. 2). Seventy-two percent of patients with
known malignancy at the time of ARDS were found to
have malignancy as the underlying cause of death at
1 year. There were no significant differences in underly-
ing cause of death between patients who died in the
hospital and patients who died after discharge.
Discussion
Short-term mortality in ARDS has declined over the last
decade owing to improvements in supportive care and of
the use of protective ventilator strategies [9, 10]. We
sought to quantify the survival gap between short- and
long-term ARDS mortality and identify risk factors for
death and causes of death at 1 year for hospital survivors.
In this study of a broad, heterogeneous cohort of critically
ill patients with ALI/ARDS, overall hospital mortality
was 24 %, concordant with short-term mortality rates of
ALI/ARDS mortality reported in the era of low tidal
volume ventilation [10, 11], and 1-year mortality was
substantially higher at 41 %, consistent with other recent
studies [11, 18, 19]. This finding did not vary according to
etiology of ARDS or in the presence of sepsis. Further-
more, in a large subgroup of patients followed for 2 years,
we found that more than half of the patients with ALI/
ARDS had died. Disposition after hospitalization was
highly associated with 1-year mortality, suggesting that
functional status after discharge may be an important
contributing factor to long-term mortality after ARDS.
The independent predictors of death at 1 year were age,
living somewhere other than home prior to admission, and
serious comorbidities. Although several measures of
severity of illness and characteristics of hospital course
were associated with long-term mortality among hospital
survivors, only length of hospital stay remained an inde-
pendent predictor of long-term mortality in a stepwise
elimination model. Restriction of the analysis to patients
meeting the Berlin definition for ARDS did not change
the findings, and Berlin level of severity of ARDS did not
predict long-term mortality in hospital survivors.
This study provides several insights into recent reports
of declines in ARDS mortality. Although short-term
mortality in ARDS has decreased in the last decade, our
findings expand upon other recent studies demonstrating a
widening survival gap between ARDS survival at dis-
charge and long-term follow-up [11, 18, 19]. This gap
suggests that while modern ICU interventions have
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improved short-term outcomes in ARDS, other factors
contribute to a persistently high long-term mortality in
ARDS. One possible explanation is the temporal changes
in characteristics of ICU patients over the last several
decades. Large studies have demonstrated that older age,
the number of comorbidities, and the severity of illness
have increased both in the general ICU population and in
ARDS patients specifically [10, 13]. ICU treatment can-
not address the underlying comorbidities and increasing
age that ultimately contribute to high long-term mortality
in ICU patients today. Although a recent study found that
adherence to low tidal volume ventilation in ARDS was
associated with a survival benefit up to 2 years following
hospitalization, these conclusions may only be
generalizable to the most healthy of ARDS patients
because those with significant comorbidities, poor social
status, and life-limiting illnesses were excluded from
enrollment in the observational study [19].
Our findings are consistent with prior studies focusing
on long-term mortality in general critically ill patients, a
finding that supports the hypothesis that long-term out-
comes in ARDS are more related to the medical
conditions and age of patients requiring ICU care in
general rather than the development of ARDS specifically
[30]. In a recent study of Medicare patients, ICU survi-
vors had higher 3-year mortality than non-ICU hospital
survivors or non-hospitalized controls, and a separate
study showed that critically ill patients have decreased
Table 1 Baseline demographics, comorbidities, and clinical characteristics in 646 patients enrolled in VALID with ALI/ARDS
Died in the hospital
(n = 153)
Survived hospitalization,
dead at 1 year (n = 110)
P value* Alive at 1 year
(n = 383)
P value
Baseline demographics
Age, mean ± SD 58 ± 17 58 ± 17 0.96 48 ± 17 \0.001
Male 87 (57 %) 64 (58 %) 0.83 232 (61 %) 0.65
Race 0.21 0.29
White 141 (92 %) 94 (85 %) 310 (81 %)
Black 10 (7 %) 15 (14 %) 57 (15 %)
Other 2 (1 %) 1 (1 %) 16 (4 %)
Home prior to hospitalization 91 (59 %) 64 (58 %) 0.83 258 (67 %) 0.08
Source of admission 0.32 0.01
Emergency department 54 (35 %) 38 (35 %) 188 (49 %)
Transfer from floor 60 (39 %) 37 (34 %) 72 (19 %)
Outside hospital 28 (18 %) 19 (17 %) 60 (16 %)
Operating room 11 (7 %) 15 (14 %) 60 (16 %)
Other 0 (0 %) 1 (1 %) 3 (1 %)
Comorbidities
COPD 17 (11 %) 26 (24 %) 0.007 39 (10 %) 0.001
HIV 5 (3 %) 8 (7 %) 0.14 6 (2 %) 0.001
Diabetes 41 (27 %) 32 (29 %) 0.68 76 (20 %) 0.04
Cirrhosis 15 (10 %) 8 (7 %) 0.47 18 (5 %) 0.29
Congestive heart failure 26 (17 %) 10 (9 %) 0.07 22 (6 %) 0.21
Chronic kidney disease 24 (16 %) 20 (18 %) 0.59 26 (7 %) \0.001
Non-metastatic cancer 19 (12 %) 17 (15 %) 0.48 25 (7 %) 0.003
Hematologic malignancya 29 (19 %) 11 (10 %) 0.05 11 (3 %) 0.001
Metastatic cancer 21 (7 %) 18 (16 %) 0.02 10 (3 %) \0.001
Baseline clinical characteristics
Primary ARDS risk factor 0.78 \0.001
Sepsis (non-pulmonary) 58 (38 %) 47 (43 %) 85 (22 %)
Pneumonia 34 (22 %) 26 (24 %) 65 (17 %)
Trauma 20 (13 %) 13 (12 %) 161 (42 %)
Aspiration 25 (16 %) 17 (15 %) 45 (12 %)
Other 16 (10 %) 7 (6 %) 27 (7 %)
Respiratory rate, mean ± SD 32 ± 8 31 ± 9 0.22 29 ± 8 0.02
PaO2/FiO2, mean ± SD
b 144 ± 78 175 ± 91 0.01 164 ± 85 0.20
Coagulation failure 48 (31 %) 30 (27 %) 0.47 67 (17 %) 0.02
Renal failure 54 (35 %) 31 (28 %) 0.22 59 (15 %) 0.002
Circulatory failure 115 (75 %) 75 (68 %) 0.21 223 (58 %) 0.06
Hepatic failure 38 (25 %) 15 (14 %) 0.03 35 (9 %) 0.17
APACHE II, mean ± SD 30 ± 8 29 ± 8 0.12 26 ± 7 0.002
LIS, mean ± SD 2.9 ± 0.7 2.8 ± 0.7 0.11 2.7 ± 0.7 0.64
ARDS acute respiratory distress syndrome, HIV human immuno-
deficiency virus, SD standard deviation, APACHE acute physiology
and chronic health evaluation, LIS lung injury score
* P value compares values in patients who died in the hospital to
those who survived hospitalization but died in the first year
 P value compares values in hospital survivors who died at 1 year
versus those alive at 1 year
a Leukemia including chronic, acute, and following stem cell
transplant
b PaO2/FiO2 missing in 142 patients; SpO2/FiO2 used as surrogate
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survival for up to 15 years compared to age- and sex-
matched population controls [40, 41]. Furthermore, pre-
dictors of long-term outcomes for critically ill patients are
similar to those we observed in ARDS, with comorbidities
as top predictors for subsequent re-hospitalization and
death [41]. One possible explanation for the persistently
high risk of death in patients with critical illness includes
a persistent pro-inflammatory state that may exacerbate or
trigger other underlying inflammatory disorders including
cardiovascular disease, recurrent infection, cancer, and
renal failure—all common causes of death among patients
in our study who survived to hospital discharge.
This study has several strengths including the large
sample size, broad patient population with few exclusion
criteria, and the careful prospective phenotyping for ALI/
ARDS, sepsis, and other important clinical variables.
Because there were very few exclusion criteria for
enrollment in VALID, the findings are likely to be gen-
eralizable. The study also has some limitations. First, it is
a single-center study. However, this is counterbalanced by
the broad spectrum of heterogeneous critically ill patients
from four different intensive care units included. Second,
it is possible that we underestimated the 1-year mortality
rate of ARDS survivors; although the SSDI has been
shown to be a valuable tool for determining long-term
outcomes [39], some patients without social security
numbers may not be included. Third, mortality does not
capture the full burden of disease. Long-term sequelae of
ARDS, including impaired pulmonary function, neuro-
muscular weakness, and neuropsychiatric are well
described [15, 42–45]. However, these limitations would
have led us to underestimate rather than overestimate
Fig. 1 Probability of survival to 1 year of follow-up among
hospital survivors according to discharge location. Whereas 15 %
(34/230) and 13 % (15/115) of patients discharged to home or
rehabilitation died in the year of follow-up, respectively, 25 % (19/
76) transferred to another hospital, 38 % (19/50) discharged to a
nursing home, and 96 % (22/23) discharged to hospice care died.
The differences in survival across groups are statistically significant
(P \ 0.001) driven by significantly increased 1-year mortality
among patients discharged to hospice (P \ 0.001), nursing home
(P \ 0.001), and other hospital (P = 0.03) compared to discharge
to home
Table 2 Characteristics of hospital course among 493 patients with ALI/ARDS surviving hospitalization
Survived hospitalization,
dead at 1 year (n = 110)
Alive at 1 year
(n = 383)
P value*
Time from admission to ICU in days, median (IQR) 0 (0–3) 0 (0–1) 0.007
Length of hospital stay in days, median (IQR) 17 (11–32) 16 (10–24) 0.09
Creatinine at discharge, median (IQR) 1.0 (0.7–1.8) 0.8 (0.7–1.1) 0.005
Discharge locationa \0.001
Home 34 (31 %) 196 (51 %)
Rehabilitation 15 (14 %) 98 (26 %)
Nursing home 19 (17 %) 31 (8 %)
Hospice 22 (20 %) 1 (\ 1 %)
Other hospital 19 (17 %) 57 (15 %)
Data are presented as n (%) unless otherwise specified
* No statistically significant difference (P [ 0.10) across groups for
length of ICU stay, in days (P = 0.76) and days of mechanical
ventilation (P = 0.62)
a Discharge data missing in one patient
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long-term effects of ARDS and do not weaken the find-
ings. Finally, we were unable to test the effect of specific
ICU interventions such as low-tidal volume ventilation on
long-term outcomes.
Conclusions
Long-term mortality is substantially higher than short-
term mortality in a broad sample of patients with ARDS.
In spite of improvements in supportive care and signifi-
cantly improved short-term outcomes, long-term
outcomes remain poor. The top predictors of 1-year
mortality in hospital survivors include non-modifiable
factors including age and comorbidities, and the most
common causes of death are malignancy and infection.
These results underscore the importance of considering
the interaction between comorbid illness and ARDS on
the trajectory of long-term outcomes in hospital survivors
of ARDS for testing new interventions and providing
prognoses. Researchers must measure whether effects of
interventions can influence the overall trajectory of sur-
vival in ARDS patients who do and do not have major
comorbidities. Possible clinical applications of such
research include improved guidance of initial discussions
of prognosis and the benefits of full resuscitation for high-
risk patients. For clinical trials, it is perhaps more realistic
to target shorter-term endpoints such as 30- to 90-day
mortality, since 1-year mortality will be driven primarily
by comorbidities that cannot be reversed or influenced by
treatments for increasing survival from ARDS such as
lung protective or prone ventilation. This study, along
with others, demonstrates that premorbid illnesses are the
top predictors of long-term outcomes after ARDS in
critically ill patients today.
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Table 3 Independent predictors of 1-year mortality among hospital survivors of ALI/ARDS (from date of discharge to 1 year following
enrollment)
Predictor Odds ratio Z score 95 % CI P value
HIV 10.83 3.90 3.26–35.89 \0.001
Metastatic cancer 9.44 4.87 3.83–23.29 \0.001
Hematologic malignancya 6.35 3.73 2.40–16.80 \0.001
Non-metastatic cancer 2.95 2.91 1.42–6.13 0.004
Chronic kidney disease 2.28 2.19 1.09–4.77 0.03
Age (in 10 years) 1.36 3.72 1.16–1.60 \0.001
Length of hospital stay (in days) 1.03 2.94 1.01–1.04 0.003
Lived at home prior to admissionb 0.48 -2.72 0.28–0.81 0.006
Trauma cause of ARDS 0.53 -1.85 0.27–1.04 0.06
The C-statistic for the final model is 0.81. Used all variables
(except discharge location) from Tables 1, 2, 3 with P \ 0.1 for
multivariable analysis using forward stepwise elimination set at
P \ 0.05
a Leukemia including chronic, acute, and following stem cell
transplant
b Home versus any other admission source
Fig. 2 Underlying causes of death in patients with ALI/ARDS who
died during the hospital stay (gray bars) and those who survived
hospitalization but died during the year following enrollment (black
bars). In both groups, the most common cause of death was
underlying malignancy. No difference is statistically significant
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